Aptorum Group's Annual General Meeting Results

Aptorum Group Limited, a clinical stage biopharmaceutical company, announces the results of its 2023 annual general meeting of shareholders. The company focuses on treating unmet medical needs in oncology, autoimmune diseases, and infectious diseases, with completed phase I clinical trials for small molecule drugs and commercialization of a nutraceutical for menopause. The pipeline includes drug discovery platforms and molecular-based rapid pathogen identification and detection diagnostics technology.